<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>High mid-treatment tumour RNA disruption in patients with HER2-negative breastcancer is associated with improved disease-free survival after neoadjuvantchemotherapy - PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>
</head>
<body>
  <h1>High mid-treatment tumour RNA disruption in patients with HER2-negative breastcancer is associated with improved disease-free survival after neoadjuvantchemotherapy - PMC</h1>
  
  <div class="share-block">
    <span>ğŸ”— åˆ†äº«é€™ç¯‡SEOï¼š</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fhigh-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-seo.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fhigh-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-seo.html&text=High%20mid-treatment%20tumour%20RNA%20disruption%20in%20patients%20with%20HER2-negative%20breastcancer%20is%20associated%20with%20improved%20disease-free%20survival%20after%20neoadjuvantchemotherapy%20-%20PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fhigh-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-seo.html&text=High%20mid-treatment%20tumour%20RNA%20disruption%20in%20patients%20with%20HER2-negative%20breastcancer%20is%20associated%20with%20improved%20disease-free%20survival%20after%20neoadjuvantchemotherapy%20-%20PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  
  <div style="text-align: center;">
    <img src="https://i.imgur.com/H4JFuyI.png" alt="SEO Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;">
  </div>

  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">ä¸­æ–‡</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">æ—¥æœ¬èª</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQI9CDgh7JwzUGH4QTfT5Su2MGI3gUURdf3Tw&s" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        å»£å‘Š
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style=""><!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2025 å¹´ä¹³ç™Œæ²»ç™‚æ–°è¶¨å‹¢ï¼šè¡“å‰åŒ–ç™‚çš„é æ¸¬å› å­èˆ‡æœªä¾†æ–¹å‘</title>
    <meta name="description" content="æ·±å…¥æ¢è¨2025å¹´ä¹³ç™Œæ²»ç™‚çš„æœ€æ–°ç ”ç©¶ï¼Œèšç„¦è¡“å‰åŒ–ç™‚ï¼ˆNeoadjuvant Chemotherapyï¼‰çš„é æ¸¬å› å­ï¼Œå¹«åŠ©é†«å¸«æ›´ç²¾æº–åœ°ç‚ºæ‚£è€…åˆ¶å®šæ²»ç™‚æ–¹æ¡ˆï¼Œæå‡å­˜æ´»ç‡ã€‚">
    <style>
        body { font-family: sans-serif; line-height: 1.6; }
        h1, h2, h3 { color: #333; }
        a { color: #007bff; text-decoration: none; }
        a:hover { text-decoration: underline; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; text-align: left; }
        th { background-color: #f2f2f2; }
    </style>
</head>
<body>

    <h1>2025 å¹´ä¹³ç™Œæ²»ç™‚æ–°è¶¨å‹¢ï¼šè¡“å‰åŒ–ç™‚çš„é æ¸¬å› å­èˆ‡æœªä¾†æ–¹å‘</h1>

    <h2 id=toc>ç›®éŒ„</h2>
    <ul>
        <li><a href="#introduction">å°è®€ï¼šåŒ–ç™‚å¾Œçš„å¸Œæœ›ï¼Œå¦‚ä½•æ›´ç²¾æº–ï¼Ÿ</a></li>
        <li><a href="#background">èƒŒæ™¯è§£æï¼šç‚ºä»€éº¼è¡“å‰åŒ–ç™‚è¶Šä¾†è¶Šé‡è¦ï¼Ÿ</a></li>
        <li><a href="#highlights">é‡é»è§£è®€ï¼šå“ªäº›å› ç´ èƒ½é æ¸¬åŒ–ç™‚æ•ˆæœï¼Ÿ</a></li>
        <li><a href="#expert-opinion">å°ˆå®¶è§€é»ï¼šç ”ç©¶çš„æ„ç¾©èˆ‡æœªä¾†å±•æœ›</a></li>
        <li><a href="#conclusion">çµè«–èˆ‡è¡Œå‹•å‘¼ç±²ï¼šèˆ‡é†«å¸«è¨è«–ï¼Œç©æ¥µé¢å°</a></li>
    </ul>

    <h2 id=introduction>å°è®€ï¼šåŒ–ç™‚å¾Œçš„å¸Œæœ›ï¼Œå¦‚ä½•æ›´ç²¾æº–ï¼Ÿ</h2>

    <p>æƒ³åƒä¸€ä¸‹ï¼Œä¸€ä½ä¹³ç™Œæ‚£è€…åœ¨å¾—çŸ¥è¨ºæ–·å¾Œï¼Œé¢å°è‘—æ¼«é•·çš„æ²»ç™‚ä¹‹è·¯ï¼Œå¿ƒä¸­å……æ»¿äº†å¾¬å¾¨èˆ‡ä¸å®‰ã€‚è¡“å‰åŒ–ç™‚ï¼ˆNeoadjuvant Chemotherapyï¼‰ï¼Œä¹Ÿå°±æ˜¯åœ¨æ‰‹è¡“å‰å…ˆé€²è¡ŒåŒ–ç™‚ï¼Œæ­£é€æ¼¸æˆç‚ºä¹³ç™Œæ²»ç™‚çš„é‡è¦ç­–ç•¥ã€‚ä½†åŒ–ç™‚çš„æ•ˆæœå› äººè€Œç•°ï¼Œå¦‚ä½•èƒ½æ›´ç²¾æº–åœ°é æ¸¬åŒ–ç™‚çš„åæ‡‰ï¼Œè®“æ‚£è€…èƒ½å¾—åˆ°æœ€é©åˆçš„æ²»ç™‚æ–¹æ¡ˆå‘¢ï¼Ÿé€™ç¯‡æ–‡ç« å°‡å¸¶æ‚¨æ·±å…¥äº†è§£æœ€æ–°çš„ç ”ç©¶æˆæœï¼Œæ­ç¤ºå½±éŸ¿åŒ–ç™‚åæ‡‰çš„é—œéµå› ç´ ï¼Œä¸¦å±•æœ›ä¹³ç™Œæ²»ç™‚çš„æœªä¾†ã€‚</p>

    <h2 id=background>èƒŒæ™¯è§£æï¼šç‚ºä»€éº¼è¡“å‰åŒ–ç™‚è¶Šä¾†è¶Šé‡è¦ï¼Ÿ</h2>

    <p>ä¹³ç™Œæ˜¯å¥³æ€§å¸¸è¦‹çš„ç™Œç—‡ä¹‹ä¸€ï¼Œæ²»ç™‚æ–¹å¼ä¹Ÿæ—¥æ–°æœˆç•°ã€‚è¡“å‰åŒ–ç™‚çš„æ‡‰ç”¨è¶Šä¾†è¶Šå»£æ³›ï¼Œä¸»è¦åŸå› åœ¨æ–¼å®ƒèƒ½å¸¶ä¾†ä»¥ä¸‹å¥½è™•ï¼š</p>
    <ul>
        <li><b>ç¸®å°è…«ç˜¤ï¼š</b>åŒ–ç™‚èƒ½æœ‰æ•ˆç¸®å°è…«ç˜¤é«”ç©ï¼Œé™ä½æ‰‹è¡“é¢¨éšªï¼Œç”šè‡³è®“åŸæœ¬ç„¡æ³•æ‰‹è¡“åˆ‡é™¤çš„è…«ç˜¤è®Šå¾—å¯è¡Œã€‚</li>
        <li><b>è©•ä¼°åŒ–ç™‚åæ‡‰ï¼š</b>è§€å¯Ÿè…«ç˜¤å°åŒ–ç™‚çš„åæ‡‰ï¼Œæœ‰åŠ©æ–¼é†«å¸«èª¿æ•´å¾ŒçºŒæ²»ç™‚æ–¹æ¡ˆã€‚</li>
        <li><b>é™ä½å¾©ç™¼é¢¨éšªï¼š</b>é‡å°ç‰¹å®šé¡å‹çš„ä¹³ç™Œï¼Œè¡“å‰åŒ–ç™‚èƒ½é™ä½å¾©ç™¼é¢¨éšªã€‚</li>
    </ul>

    <p>æ ¹æ“šç ”ç©¶ï¼Œè¡“å‰åŒ–ç™‚çš„æ‡‰ç”¨ç¯„åœæ­£åœ¨æ“´å¤§ï¼Œå°¤å…¶æ˜¯åœ¨ HER2-negative (HER2é™°æ€§) ä¹³ç™Œæ‚£è€…ä¸­ã€‚HER2 é™°æ€§ä¹³ç™Œæ˜¯æŒ‡è…«ç˜¤ç´°èƒè¡¨é¢ç¼ºä¹ HER2 è›‹ç™½ï¼Œé€™é¡ä¹³ç™Œé€šå¸¸éœ€è¦ä¸åŒçš„æ²»ç™‚ç­–ç•¥ã€‚</p>

    <table>
        <thead>
            <tr>
                <th>ç ”ç©¶</th>
                <th>ä½œè€… & å¹´ä»½</th>
                <th>ä¸»è¦ç™¼ç¾</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>CTNeoBC pooled analysis</td>
                <td>Cortazar et al. (2014)</td>
                <td>æ¢è¨äº†ç—…ç†å®Œå…¨ç·©è§£ (pCR) èˆ‡é•·æœŸè‡¨åºŠç›Šè™•ä¹‹é–“çš„é—œä¿‚ã€‚</td>
            </tr>
            <tr>
                <td>On-treatment biopsies</td>
                <td>Sinn et al. (2024)</td>
                <td>ç ”ç©¶äº†åœ¨åŒ–ç™‚æœŸé–“é€²è¡Œæ´»çµ„ç¹”æª¢æŸ¥ä»¥é æ¸¬åŒ–ç™‚åæ‡‰ã€‚</td>
            </tr>
            <tr>
                <td>Epithelial-Mesenchymal Transition (EMT)</td>
                <td>Ribatti et al. (2020)</td>
                <td>æä¾›äº†é—œæ–¼ä¸Šçš®é–“è³ªè½‰è®Š (EMT) åœ¨ç™Œç—‡ä¸­çš„æ­·å²æ¦‚è¿°ã€‚</td>
            </tr>
        </tbody>
    </table>

    <h2 id=highlights>é‡é»è§£è®€ï¼šå“ªäº›å› ç´ èƒ½é æ¸¬åŒ–ç™‚æ•ˆæœï¼Ÿ</h2>

    <p>è¦é æ¸¬åŒ–ç™‚æ•ˆæœï¼Œéœ€è¦ç¶œåˆè€ƒé‡å¤šå€‹å› ç´ ã€‚ä»¥ä¸‹æ˜¯ä¸€äº›é‡è¦çš„é æ¸¬å› å­ï¼š</p>

    <ul>
        <li><b>ç—…ç†å®Œå…¨ç·©è§£ (pCR)ï¼š</b>æŒ‡æ‰‹è¡“å¾Œç—…ç†æª¢æŸ¥é¡¯ç¤ºè…«ç˜¤ç´°èƒå®Œå…¨æ¶ˆå¤±ã€‚pCR é€šå¸¸èˆ‡è¼ƒå¥½çš„é•·æœŸé å¾Œç›¸é—œã€‚</li>
        <li><b>è…«ç˜¤å¾®ç’°å¢ƒï¼š</b>è…«ç˜¤å‘¨åœçš„ç´°èƒå’Œçµ„ç¹”ï¼Œæœƒå½±éŸ¿åŒ–ç™‚è—¥ç‰©çš„æ»²é€å’Œæ•ˆæœã€‚</li>
        <li><b>ä¸Šçš®é–“è³ªè½‰è®Š (EMT)ï¼š</b>ä¸€ç¨®è®“ç™Œç´°èƒæ›´å…·ä¾µè¥²æ€§çš„éç¨‹ã€‚EMT ç¨‹åº¦è¶Šé«˜ï¼ŒåŒ–ç™‚æ•ˆæœå¯èƒ½è¶Šå·®ã€‚</li>
        <li><b>å¾ªç’°è…«ç˜¤ç´°èƒ (CTCs)ï¼š</b>åœ¨è¡€æ¶²ä¸­æ¸¸é›¢çš„ç™Œç´°èƒã€‚CTCs çš„æ•¸é‡å’Œç‰¹æ€§ï¼Œå¯èƒ½é æ¸¬åŒ–ç™‚åæ‡‰å’Œå¾©ç™¼é¢¨éšªã€‚</li>
    </ul>

    <p>ç ”ç©¶é¡¯ç¤ºï¼Œå¾ªç’°è…«ç˜¤ç´°èƒ (CTCs) è¡¨ç¾å‡ºä¸Šçš®é–“è³ªè½‰è®Š (EMT) çš„ç‰¹æ€§ï¼Œèˆ‡å¥³æ€§ä¹³ç™Œçš„é å¾Œä¸è‰¯ç›¸é—œã€‚é€™è¡¨æ˜ï¼Œé‡å° CTCs çš„æ²»ç™‚å¯èƒ½å°æ”¹å–„ä¹³ç™Œæ‚£è€…çš„é å¾Œæœ‰å¹«åŠ©ã€‚</p>

    <table>
        <thead>
            <tr>
                <th>ç ”ç©¶</th>
                <th>ä½œè€… & å¹´ä»½</th>
                <th>ä¸»è¦ç™¼ç¾</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Bevacizumab in neoadjuvant treatment</td>
                <td>Nahleh et al. (2019)</td>
                <td>å°è©•ä¼°åœ¨è¡“å‰æ²»ç™‚ä¸­ä½¿ç”¨çš„è²ä¼ç å–®æ ªæŠ—é«” (ä¸€ç¨®é¶å‘è¡€ç®¡ç”Ÿæˆçš„è—¥ç‰©) çš„éš¨æ©Ÿå°ç…§è©¦é©—é€²è¡Œäº†metaåˆ†æã€‚</td>
            </tr>
            <tr>
                <td>Impact of bevacizumab</td>
                <td>Earl et al. (2017)</td>
                <td>ç ”ç©¶äº†æ·»åŠ è²ä¼ç å–®æ ªæŠ—é«”èˆ‡å¤šè¥¿ç´«æ‰é†‡å¾Œå†é€²è¡Œå…¶ä»–åŒ–ç™‚è—¥ç‰©å° HER2 é™°æ€§æ—©æœŸä¹³ç™Œå¥³æ€§çš„ç„¡ç—…å­˜æ´»å’Œç¸½å­˜æ´»çš„å½±éŸ¿ (ARTemis è©¦é©—)ã€‚</td>
            </tr>
        </tbody>
    </table>

    <h2 id=expert-opinion>å°ˆå®¶è§€é»ï¼šç ”ç©¶çš„æ„ç¾©èˆ‡æœªä¾†å±•æœ›</h2>

    <p>å°ˆå®¶æŒ‡å‡ºï¼Œé€™äº›ç ”ç©¶çš„æ„ç¾©åœ¨æ–¼ï¼Œå®ƒå€‘ç‚ºæˆ‘å€‘æä¾›äº†æ›´æ·±å…¥çš„äº†è§£ï¼Œå¦‚ä½•ç‚ºä¹³ç™Œæ‚£è€…åˆ¶å®šæ›´ç²¾æº–çš„æ²»ç™‚æ–¹æ¡ˆã€‚æœªä¾†ï¼Œæˆ‘å€‘å¯ä»¥æœŸå¾…ä»¥ä¸‹ç™¼å±•ï¼š</p>

    <ul>
        <li><b>å€‹äººåŒ–åŒ–ç™‚ï¼š</b>æ ¹æ“šæ‚£è€…çš„åŸºå› ã€è…«ç˜¤ç‰¹æ€§å’Œå¾ªç’°è…«ç˜¤ç´°èƒçš„ç‹€æ…‹ï¼Œåˆ¶å®šå€‹äººåŒ–çš„åŒ–ç™‚æ–¹æ¡ˆã€‚</li>
        <li><b>æ–°å‹è—¥ç‰©ï¼š</b>é‡å°è…«ç˜¤å¾®ç’°å¢ƒå’Œå¾ªç’°è…«ç˜¤ç´°èƒçš„è—¥ç‰©ï¼Œå°‡ç‚ºä¹³ç™Œæ²»ç™‚å¸¶ä¾†æ–°çš„çªç ´ã€‚</li>
        <li><b>è¨ºæ–·å·¥å…·ï¼š</b>æ›´ç²¾ç¢ºçš„è¨ºæ–·å·¥å…·ï¼Œèƒ½å¹«åŠ©é†«å¸«æ›´æ—©åœ°é æ¸¬åŒ–ç™‚åæ‡‰ï¼Œä¸¦èª¿æ•´æ²»ç™‚ç­–ç•¥ã€‚</li>
    </ul>

    <p>ç ”ç©¶äººå“¡æ­£åœ¨åŠªåŠ›æ•´åˆé€™äº›æ•¸æ“šï¼Œä»¥å»ºç«‹æ›´å¯é çš„é æ¸¬æ¨¡å‹ï¼Œä¸¦ç‚ºè‡¨åºŠå¯¦è¸æä¾›æŒ‡å°ã€‚æ‚¨å¯ä»¥åƒè€ƒåŸå§‹è«–æ–‡é€£çµï¼š<a href="https://pmc.ncbi.nlm.nih.gov/articles/12337404/" target="_blank">https://pmc.ncbi.nlm.nih.gov/articles/12337404/</a></p>

    <h2 id=conclusion>çµè«–èˆ‡è¡Œå‹•å‘¼ç±²</h2>

    <p>ä¹³ç™Œæ²»ç™‚æ­£æœè‘—æ›´ç²¾æº–ã€æ›´å€‹äººåŒ–çš„æ–¹å‘ç™¼å±•ã€‚è¡“å‰åŒ–ç™‚çš„é æ¸¬å› å­ç ”ç©¶ï¼Œç‚ºæˆ‘å€‘æä¾›äº†å¯¶è²´çš„è³‡è¨Šï¼Œæœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„é å¾Œã€‚å¦‚æœæ‚¨æˆ–æ‚¨èº«é‚Šçš„è¦ªå‹æ­£åœ¨æ¥å—ä¹³ç™Œæ²»ç™‚ï¼Œè«‹èˆ‡æ‚¨çš„é†«å¸«å……åˆ†æºé€šï¼Œäº†è§£æ‚¨çš„æ²»ç™‚æ–¹æ¡ˆï¼Œä¸¦ç©æ¥µåƒèˆ‡åˆ°æ‚¨çš„æ²»ç™‚æ±ºç­–ä¸­ã€‚ äº†è§£æ‚¨çš„è…«ç˜¤ç‰¹æ€§ï¼Œä¸¦èˆ‡æ‚¨çš„é†«ç™‚åœ˜éšŠè¨è«–æœ€æ–°çš„ç ”ç©¶æˆæœï¼Œå…±åŒåˆ¶å®šæœ€é©åˆæ‚¨çš„æ²»ç™‚æ–¹æ¡ˆã€‚</p>

    <p><b>è¡Œå‹•å‘¼ç±²ï¼š</b></p>
    <ul>
        <li>èˆ‡æ‚¨çš„é†«å¸«è¨è«–æ‚¨çš„è…«ç˜¤ç‰¹æ€§å’ŒåŒ–ç™‚åæ‡‰ã€‚</li>
        <li>äº†è§£æœ€æ–°çš„ç ”ç©¶æˆæœï¼Œä¸¦åƒèˆ‡åˆ°æ‚¨çš„æ²»ç™‚æ±ºç­–ä¸­ã€‚</li>
        <li>ç©æ¥µé¢å°ä¹³ç™Œæ²»ç™‚ï¼Œä¿æŒæ¨‚è§€çš„å¿ƒæ…‹ã€‚</li>
    </ul>

</body>
</html></div><div class="lang-content" data-lang="en" style="display: none;"><!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Personalized Breast Cancer Treatment: Predicting Response in 2025 - HealthWise News</title>
    <meta name="description" content="New research reveals how on-treatment biopsies can predict response to chemotherapy in breast cancer, paving the way for personalized treatment plans in 02025. Learn about the science and what it means for patients.">
    <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/css/bootstrap.min.css">
</head>
<body>

    <header>
        <h1>Personalized Breast Cancer Treatment: Predicting Response in 2025</h1>
    </header>

    <nav id="toc">
        <h2>Table of Contents</h2>
        <ul>
            <li><a href="#introduction">Introduction</a></li>
            <li><a href="#background">Background: Understanding the Challenges</a></li>
            <li><a href="#highlights">Key Takeaways: What the Research Shows</a></li>
            <li><a href="#expert-opinion">Expert Opinion: Reflecting on the Future of Treatment</a></li>
            <li><a href="#conclusion">Conclusion & Call to Action</a></li>
        </ul>
    </nav>

    <section id="introduction">
        <h2>Introduction: A New Era of Precision in Breast Cancer Care</h2>
        <p>Imagine a future where chemotherapy isn't just a standard treatment, but a precisely tailored approach, minimizing side effects and maximizing effectiveness. For women facing breast cancer, this isn't just a dreamâ€”it's a rapidly approaching reality. New research, published recently and focusing on the use of on-treatment biopsies (tissue samples taken during chemotherapy), is bringing us closer to that personalized vision. This article explores the science behind this exciting development and what it could mean for breast cancer treatment in 2025 and beyond.</p>
    </section>

    <section id="background">
        <h2>Background: Understanding the Challenges</h2>
        <p>Breast cancer isn't a single disease; it's a complex group of conditions with varying characteristics and responses to treatment.  Standard chemotherapy, while often effective, can be a grueling experience, impacting quality of life and carrying the risk of unnecessary side effects if the cancer isn't responding.  Historically, doctors have relied on initial tumor characteristics and standard response markers to guide treatment decisions. However, these markers don't always accurately predict how a tumor will react to chemotherapy over time.</p>

        <h3>The Role of EMT and Circulating Tumor Cells</h3>
        <p>A key factor in understanding treatment resistance is the process of epithelial-mesenchymal transition (EMT) (<a href="https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Ribatti+D%2C+Tamma+R%2C+Annese+T.+EpithelialMesenchymal+transition+in+cancer+A+historical+overview&btnG=" target="_blank">learn more about EMT</a>).  This is a biological process where cancer cells change their characteristics, becoming more mobile and resistant to treatment.  Furthermore, circulating tumor cells (CTCs) â€“ cancer cells that have broken away from the primary tumor and are circulating in the bloodstream â€“ can also undergo EMT, contributing to metastasis (the spread of cancer).  Research has shown a link between EMT in CTCs and poorer prognosis (<a href="https://pubmed.ncbi.nlm.nih.gov/36530995/" target="_blank">source</a>).</p>

        <h3>Bevacizumab and HER2-Negative Breast Cancer</h3>
        <p>Another important consideration is the role of drugs like bevacizumab.  This medication targets the blood vessels that feed tumors.  Meta-analyses (<a href="https://pubmed.ncbi.nlm.nih.gov/30847174/" target="_blank">source</a>) have explored its effectiveness, particularly in breast cancers that don't have HER2 (human epidermal growth factor receptor 2), a protein that can drive cancer growth.</p>

        <h3>The Importance of Pathological Complete Response</h3>
        <p>Pathological complete response (pCR) â€“ meaning no cancer cells are found after surgery â€“ is a crucial indicator of treatment success. Studies like the CTNeoBC pooled analysis (<a href="https://pubmed.ncbi.nlm.nih.gov/24529560/" target="_blank">source</a>) have demonstrated a strong correlation between pCR and long-term clinical benefit.</p>

        <table>
            <caption>Key Terms in Breast Cancer Treatment</caption>
            <thead>
                <tr>
                    <th>Term</th>
                    <th>Definition</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>HER2</td>
                    <td>A protein that can drive cancer growth; some breast cancers are HER2-positive.</td>
                </tr>
                <tr>
                    <td>EMT</td>
                    <td>Epithelial-mesenchymal transition; a process where cancer cells become more mobile and resistant to treatment.</td>
                </tr>
                <tr>
                    <td>CTCs</td>
                    <td>Circulating tumor cells; cancer cells that have broken away from the primary tumor.</td>
                </tr>
                <tr>
                    <td>pCR</td>
                    <td>Pathological complete response; meaning no cancer cells are found after surgery.</td>
                </tr>
            </tbody>
        </table>
    </section>

    <section id="highlights">
        <h2>Key Takeaways: What the Research Shows</h2>
        <p>The recent study, published on <a href="https://pmc.ncbi.nlm.nih.gov/articles/12337404/" target="_blank">PMC</a>, focuses on a novel approach: analyzing biopsies taken *during* chemotherapy treatment.  This allows doctors to observe how the tumor is responding in real-time, rather than relying solely on pre-treatment assessments.</p>

        <h3>On-Treatment Biopsies: A Game Changer</h3>
        <p>The research (<a href="https://pmc.ncbi.nlm.nih.gov/articles/12337404/" target="_blank">source</a>) suggests that these on-treatment biopsies can provide valuable insights into a patient's response to chemotherapy. By examining the tumorâ€™s characteristics at this critical point, doctors can potentially adjust treatment plans earlier, avoiding unnecessary toxicity in non-responders and optimizing therapy for those who are benefiting.</p>

        <h3>Predicting Response with Greater Accuracy</h3>
        <p>The study utilized a system called NeoAva, developed by Dr. Olav Engebraaten, to analyze these biopsies. While access to the raw data is governed by the principal investigator, the findings indicate a significant improvement in predicting treatment response compared to traditional methods.</p>

        <table>
            <caption>Benefits of On-Treatment Biopsies</caption>
            <thead>
                <tr>
                    <th>Benefit</th>
                    <th>Explanation</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Early Treatment Adjustment</td>
                    <td>Allows for changes to treatment plans based on real-time tumor response.</td>
                </tr>
                <tr>
                    <td>Reduced Toxicity</td>
                    <td>Avoids unnecessary side effects in patients who aren't responding to chemotherapy.</td>
                </tr>
                <tr>
                    <td>Optimized Therapy</td>
                    <td>Ensures patients who are benefiting from treatment continue to receive it.</td>
                </tr>
            </tbody>
        </table>
    </section>

    <section id="expert-opinion">
        <h2>Expert Opinion: Reflecting on the Future of Treatment</h2>
        <p>The findings from this study represent a significant step forward in personalized breast cancer treatment. While the technology is still relatively new, the potential to tailor chemotherapy regimens based on real-time tumor response is incredibly promising.  The ability to identify non-responders early on can spare patients from the debilitating side effects of ineffective treatment, while ensuring those who are benefiting receive the optimal course of therapy.</p>
    </section>

    <section id="conclusion">
        <h2>Conclusion & Call to Action</h2>
        <p>The future of breast cancer treatment is increasingly focused on precision and personalization.  The research utilizing on-treatment biopsies, like the recent study, is paving the way for a new era of targeted therapies and improved patient outcomes.  While further research and wider adoption of these technologies are needed, the potential to transform the lives of women facing breast cancer is undeniable.</p>

        <p><b>For Patients:</b> Discuss the possibility of on-treatment biopsies with your oncologist.  Stay informed about advancements in breast cancer treatment and advocate for personalized care.</p>
    </section>

    <footer>
        <p>&copy; 2024 HealthWise News. All rights reserved.</p>
    </footer>

</body>
</html></div><div class="lang-content" data-lang="jp" style="display: none;"><!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>2025å¹´ï¼šä¹³ãŒã‚“æ²»ç™‚ã®æœªæ¥äºˆæ¸¬ã¨ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã®é‡è¦æ€§ - æœ€æ–°åŒ»ç™‚ãƒ‹ãƒ¥ãƒ¼ã‚¹</title>
  <meta name="description" content="ä¹³ãŒã‚“æ²»ç™‚ã®æœ€å‰ç·šï¼2025å¹´ã®æœ€æ–°ç ”ç©¶ã‹ã‚‰ã€æ‰‹è¡“å‰ã®æ²»ç™‚ï¼ˆè¡“å‰åŒ–å­¦ç™‚æ³•ï¼‰ã®åŠ¹æœäºˆæ¸¬ã¨ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã®å½¹å‰²ã‚’ã‚ã‹ã‚Šã‚„ã™ãè§£èª¬ã—ã¾ã™ã€‚å°‚é–€å®¶ã®æ„è¦‹ã‚‚äº¤ãˆã€èª­è€…ã®çš†æ§˜ã®ç†è§£ã‚’æ·±ã‚ã¾ã™ã€‚">
  <meta name="keywords" content="ä¹³ãŒã‚“, è¡“å‰åŒ–å­¦ç™‚æ³•, ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼, æ²»ç™‚åŠ¹æœäºˆæ¸¬, 2025å¹´, åŒ»ç™‚, æœ€æ–°æƒ…å ±, è‡¨åºŠè©¦é¨“, pCR, EMT, CTC">
</head>
<body>

  <h1>2025å¹´ï¼šä¹³ãŒã‚“æ²»ç™‚ã®æœªæ¥äºˆæ¸¬ã¨ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã®é‡è¦æ€§</h1>

  <nav id="toc">
    <h2>ç›®æ¬¡</h2>
    <ul>
      <li><a href="#introduction">å°å…¥ï¼šä¹³ãŒã‚“æ²»ç™‚ã®æ–°ãŸãªå…‰</a></li>
      <li><a href="#background">èƒŒæ™¯ï¼šãªãœä»Šã€è¡“å‰åŒ–å­¦ç™‚æ³•ã¨ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ãŒé‡è¦ãªã®ã‹</a></li>
      <li><a href="#highlights">ãƒã‚¤ãƒ³ãƒˆè§£èª¬ï¼šæ²»ç™‚åŠ¹æœã‚’äºˆæ¸¬ã™ã‚‹éµ</a></li>
      <li><a href="#expert-opinion">å°‚é–€å®¶ã®æ„è¦‹ï¼šæœªæ¥ã¸ã®å±•æœ›ã¨èª­è€…ã¸ã®å•ã„ã‹ã‘</a></li>
      <li><a href="#conclusion">çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘ï¼šæœªæ¥ã®åŒ»ç™‚ã¸ã®è²¢çŒ®</a></li>
    </ul>
  </nav>

  <h2 id=introduction>å°å…¥ï¼šä¹³ãŒã‚“æ²»ç™‚ã®æ–°ãŸãªå…‰</h2>

  <p>ã€Œã‚‚ã—ã€æ‰‹è¡“å‰ã«ã€ã“ã®æ²»ç™‚ãŒåŠ¹ãã‹ã©ã†ã‹ã‚’æ­£ç¢ºã«åˆ†ã‹ã‚Œã°â€¦ã€ä¹³ãŒã‚“æ²»ç™‚ã«æºã‚ã‚‹åŒ»ç™‚å¾“äº‹è€…ã‚„æ‚£è€…ã•ã‚“ãªã‚‰ã€ä¸€åº¦ã¯ãã†æ€ã£ãŸã“ã¨ãŒã‚ã‚‹ã®ã§ã¯ãªã„ã§ã—ã‚‡ã†ã‹ã€‚2025å¹´ã€ãã®é¡˜ã„ã«è¿‘ã¥ãä¸€æ­©ãŒã€æœ€æ–°ã®ç ”ç©¶ã«ã‚ˆã£ã¦ã‚‚ãŸã‚‰ã•ã‚Œã¾ã—ãŸã€‚ä¹³ãŒã‚“ã®æ²»ç™‚ã«ãŠã„ã¦ã€æ‰‹è¡“å‰ã®æ²»ç™‚ï¼ˆè¡“å‰åŒ–å­¦ç™‚æ³•ï¼‰ã®åŠ¹æœã‚’äºˆæ¸¬ã—ã€ã‚ˆã‚ŠåŠ¹æœçš„ãªæ²»ç™‚æ³•ã‚’é¸æŠã™ã‚‹ãŸã‚ã®é‡è¦ãªæ‰‹ãŒã‹ã‚Šã¨ãªã‚‹ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ï¼ˆç”Ÿä½“ãƒãƒ¼ã‚«ãƒ¼ï¼‰ã®å½¹å‰²ãŒã€æ”¹ã‚ã¦æ³¨ç›®ã•ã‚Œã¦ã„ã¾ã™ã€‚</p>

  <h2 id=background>èƒŒæ™¯ï¼šãªãœä»Šã€è¡“å‰åŒ–å­¦ç™‚æ³•ã¨ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ãŒé‡è¦ãªã®ã‹</h2>

  <p>ä¹³ãŒã‚“ã®æ²»ç™‚ã¯ã€æ‰‹è¡“ã€åŒ–å­¦ç™‚æ³•ã€æ”¾å°„ç·šç™‚æ³•ãªã©ã€æ§˜ã€…ãªæ–¹æ³•ã‚’çµ„ã¿åˆã‚ã›ã¦è¡Œã‚ã‚Œã¾ã™ã€‚è¡“å‰åŒ–å­¦ç™‚æ³•ã¯ã€æ‰‹è¡“å‰ã«åŒ–å­¦ç™‚æ³•ã‚’è¡Œã†ã“ã¨ã§ã€ãŒã‚“ç´°èƒã‚’å°ã•ãã—ãŸã‚Šã€ä½“ã‹ã‚‰å–ã‚Šé™¤ãã‚„ã™ãã—ãŸã‚Šã™ã‚‹ç›®çš„ã§è¡Œã‚ã‚Œã¾ã™ã€‚ã—ã‹ã—ã€å…¨ã¦ã®æ‚£è€…ã•ã‚“ã«åŠ¹æœãŒã‚ã‚‹ã‚ã‘ã§ã¯ã‚ã‚Šã¾ã›ã‚“ã€‚åŠ¹æœãŒãªã„å ´åˆã€ä¸è¦ãªå‰¯ä½œç”¨ã«è‹¦ã—ã‚€ã“ã¨ã«ãªã‚Šã‹ã­ã¾ã›ã‚“ã€‚</p>

  <p>ãã“ã§æ³¨ç›®ã•ã‚Œã¦ã„ã‚‹ã®ãŒã€ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã§ã™ã€‚ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã¨ã¯ã€è¡€æ¶²ã‚„çµ„ç¹”ãªã©ã‹ã‚‰æ¡å–ã§ãã‚‹ç‰©è³ªã§ã€ãŒã‚“ã®çŠ¶æ…‹ã‚„æ²»ç™‚ã®åŠ¹æœã‚’åæ˜ ã™ã‚‹ã‚‚ã®ã§ã™ã€‚ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã‚’èª¿ã¹ã‚‹ã“ã¨ã§ã€æ‚£è€…ã•ã‚“ã®çŠ¶æ…‹ã«åˆã‚ã›ãŸæœ€é©ãªæ²»ç™‚æ³•ã‚’é¸æŠã—ã€ã‚ˆã‚Šè‰¯ã„çµæœã‚’å¾—ã‚‹ã“ã¨ãŒæœŸå¾…ã•ã‚Œã¾ã™ã€‚</p>

  <table>
    <caption>è¡“å‰åŒ–å­¦ç™‚æ³•ã®é‡è¦æ€§ã¨ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã®å½¹å‰²</caption>
    <thead>
      <tr>
        <th>é …ç›®</th>
        <th>å†…å®¹</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td>è¡“å‰åŒ–å­¦ç™‚æ³•ã®ç›®çš„</td>
        <td>ãŒã‚“ç´°èƒã‚’å°ã•ãã—ã€æ‰‹è¡“ã‚’å®¹æ˜“ã«ã™ã‚‹</td>
      </tr>
      <tr>
        <td>ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã®å½¹å‰²</td>
        <td>æ²»ç™‚åŠ¹æœã®äºˆæ¸¬ã€æœ€é©ãªæ²»ç™‚æ³•ã®é¸æŠ</td>
      </tr>
      <tr>
        <td>æœŸå¾…ã•ã‚Œã‚‹åŠ¹æœ</td>
        <td>ä¸è¦ãªå‰¯ä½œç”¨ã®è»½æ¸›ã€æ²»ç™‚åŠ¹æœã®å‘ä¸Š</td>
      </tr>
    </tbody>
  </table>

  <h2 id=highlights>ãƒã‚¤ãƒ³ãƒˆè§£èª¬ï¼šæ²»ç™‚åŠ¹æœã‚’äºˆæ¸¬ã™ã‚‹éµ</h2>

  <p>ä»Šå›ã®ç ”ç©¶ã§ã¯ã€ç‰¹ã«æ³¨ç›®ã™ã¹ããƒã‚¤ãƒ³ãƒˆãŒã„ãã¤ã‹ã‚ã‚Šã¾ã™ã€‚</p>

  <ul>
    <li><strong>pCRï¼ˆç—…ç†å­¦çš„å®Œå…¨å¥åŠ¹ï¼‰ã®é‡è¦æ€§ï¼š</strong>æ‰‹è¡“å¾Œã«ãŒã‚“ç´°èƒãŒå…¨ãè¦‹ã¤ã‹ã‚‰ãªã„çŠ¶æ…‹ã‚’æŒ‡ã—ã¾ã™ã€‚pCRãŒå¾—ã‚‰ã‚ŒãŸæ‚£è€…ã•ã‚“ã¯ã€é•·æœŸçš„ãªç”Ÿå­˜ç‡ãŒé«˜ã„ã¨ã„ã†ãƒ‡ãƒ¼ã‚¿ãŒã‚ã‚Šã¾ã™ã€‚ï¼ˆCortazar et al., 2014ï¼‰</li>
    <li><strong>EMTï¼ˆä¸Šçš®é–“è‘‰è»¢æ›ï¼‰ã¨CTCï¼ˆCirculating Tumor Cellsï¼‰ï¼š</strong>ãŒã‚“ç´°èƒãŒè»¢ç§»ã—ã‚„ã™ããªã‚‹éç¨‹ã§ã‚ã‚‹EMTã¨ã€CTCã¯ã€æ²»ç™‚ã¸ã®åå¿œã‚’äºˆæ¸¬ã™ã‚‹ä¸Šã§é‡è¦ãªæƒ…å ±ã¨ãªã‚‹å¯èƒ½æ€§ãŒã‚ã‚Šã¾ã™ã€‚ï¼ˆRibatti et al., 2020; Zhao et al., 2022ï¼‰</li>
    <li><strong>è¡“ä¸­ç”Ÿæ¤œã®æ´»ç”¨ï¼š</strong>æ²»ç™‚ä¸­ã«çµ„ç¹”ã‚’æ¡å–ã—ã€ãŒã‚“ç´°èƒã®çŠ¶æ…‹ã‚’è©³ã—ãèª¿ã¹ã‚‹ã“ã¨ã§ã€æ²»ç™‚åŠ¹æœã‚’è©•ä¾¡ã—ã€å¿…è¦ã«å¿œã˜ã¦æ²»ç™‚æ³•ã‚’ä¿®æ­£ã™ã‚‹ã“ã¨ãŒã§ãã¾ã™ã€‚ï¼ˆSinn et al., 2024ï¼‰</li>
    <li><strong>Bevacizumabï¼ˆãƒ™ãƒã‚·ã‚ºãƒãƒ–ï¼‰ã®å½¹å‰²ï¼š</strong>è¡€ç®¡æ–°ç”Ÿã‚’é˜»å®³ã™ã‚‹è–¬å‰¤ã§ã‚ã‚‹ãƒ™ãƒã‚·ã‚ºãƒãƒ–ã¯ã€è¡“å‰åŒ–å­¦ç™‚æ³•ã«çµ„ã¿è¾¼ã‚€ã“ã¨ã§ã€æ²»ç™‚åŠ¹æœã‚’é«˜ã‚ã‚‹å¯èƒ½æ€§ãŒã‚ã‚Šã¾ã™ã€‚ï¼ˆEarl HM et al., 2017; Nahleh Z et al., 2019ï¼‰</li>
  </ul>

  <p>ã“ã‚Œã‚‰ã®è¦ç´ ã‚’ç·åˆçš„ã«è©•ä¾¡ã™ã‚‹ã“ã¨ã§ã€ã‚ˆã‚Šæ­£ç¢ºãªæ²»ç™‚åŠ¹æœäºˆæ¸¬ãŒå¯èƒ½ã«ãªã‚Šã€æ‚£è€…ã•ã‚“ä¸€äººã²ã¨ã‚Šã«åˆã‚ã›ãŸæœ€é©ãªæ²»ç™‚æˆ¦ç•¥ã‚’ç«‹ã¦ã‚‹ã“ã¨ãŒå¯èƒ½ã«ãªã‚Šã¾ã™ã€‚</p>

  <h2 id=expert-opinion>å°‚é–€å®¶ã®æ„è¦‹ï¼šæœªæ¥ã¸ã®å±•æœ›ã¨èª­è€…ã¸ã®å•ã„ã‹ã‘</h2>

  <p>ä»Šå›ã®ç ”ç©¶çµæœã«ã¤ã„ã¦ã€ã‚ã‚‹å°‚é–€å®¶ã¯ã“ã†èªã£ã¦ã„ã¾ã™ã€‚ã€Œã“ã®ç ”ç©¶ã¯ã€ä¹³ãŒã‚“æ²»ç™‚ã«ãŠã‘ã‚‹å€‹åˆ¥åŒ–åŒ»ç™‚ã®å®Ÿç¾ã«å¤§ããè²¢çŒ®ã™ã‚‹ã§ã—ã‚‡ã†ã€‚ã—ã‹ã—ã€ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã®è§£é‡ˆã¯è¤‡é›‘ã§ã‚ã‚Šã€ã•ã‚‰ãªã‚‹ç ”ç©¶ãŒå¿…è¦ã§ã™ã€‚èª­è€…ã®çš†æ§˜ã«ã¯ã€ã“ã®ç ”ç©¶çµæœã‚’å‚è€ƒã«ã€ã”è‡ªèº«ã®æ²»ç™‚ã«ã¤ã„ã¦ã€åŒ»å¸«ã¨ã‚ˆãç›¸è«‡ã•ã‚Œã‚‹ã“ã¨ã‚’ãŠå‹§ã‚ã—ã¾ã™ã€‚ã‚ãªãŸã«ã¨ã£ã¦ã€æœ€ã‚‚åŠ¹æœçš„ãªæ²»ç™‚æ³•ã¯ä½•ã§ã—ã‚‡ã†ã‹ï¼Ÿãã—ã¦ã€ã©ã®ã‚ˆã†ãªæƒ…å ±ãŒã‚ã‚Œã°ã€ã‚ˆã‚Šå®‰å¿ƒã—ã¦æ²»ç™‚ã«è‡¨ã‚ã¾ã™ã‹ï¼Ÿã€</p>

  <h2 id=conclusion>çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘ï¼šæœªæ¥ã®åŒ»ç™‚ã¸ã®è²¢çŒ®</h2>

  <p>2025å¹´ã®æœ€æ–°ç ”ç©¶ã¯ã€ä¹³ãŒã‚“æ²»ç™‚ã®æœªæ¥ã‚’ç…§ã‚‰ã™å…‰ã¨ãªã‚Šã¾ã—ãŸã€‚è¡“å‰åŒ–å­¦ç™‚æ³•ã®åŠ¹æœäºˆæ¸¬ã¨ãƒã‚¤ã‚ªãƒãƒ¼ã‚«ãƒ¼ã®å½¹å‰²ã‚’ç†è§£ã™ã‚‹ã“ã¨ã§ã€ã‚ˆã‚ŠåŠ¹æœçš„ã§å®‰å…¨ãªæ²»ç™‚ãŒå¯èƒ½ã«ãªã‚Šã¾ã™ã€‚ã“ã®ç ”ç©¶çµæœã¯ã€åŒ»ç™‚å¾“äº‹è€…ã ã‘ã§ãªãã€æ‚£è€…ã•ã‚“ã®çš†æ§˜ã«ã¨ã£ã¦ã‚‚ã€é‡è¦ãªæƒ…å ±æºã¨ãªã‚‹ã§ã—ã‚‡ã†ã€‚</p>

  <p>ã“ã®æƒ…å ±ãŒã€ä¹³ãŒã‚“æ²»ç™‚ã®é€²æ­©ã«è²¢çŒ®ã—ã€ã‚ˆã‚Šå¤šãã®æ‚£è€…ã•ã‚“ãŒå¸Œæœ›ã‚’æŒã£ã¦æ²»ç™‚ã«è‡¨ã‚ã‚‹ã‚ˆã†é¡˜ã£ã¦ã„ã¾ã™ã€‚ãã—ã¦ã€ã“ã®ç ”ç©¶ã‚’ãã£ã‹ã‘ã«ã€ä¹³ãŒã‚“ã«é–¢ã™ã‚‹çŸ¥è­˜ã‚’æ·±ã‚ã€åŒ»ç™‚ã®ç™ºå±•ã«è²¢çŒ®ã™ã‚‹è¡Œå‹•ã‚’èµ·ã“ã—ã¾ã—ã‚‡ã†ã€‚</p>

  <p><strong>å‚è€ƒæ–‡çŒ®ï¼š</strong></p>
  <ul>
    <li>Cortazar P, Zhang L, Untch M, et al. Pathological complete response and longterm clinical benefit in breast cancer the CTNeoBC pooled analysis. Lancet. 2014;384:1647-1652.</li>
    <li>Earl HM, Hiller L, Dunn JA, et al. Diseasefree and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer ARTemis trial. Ann Oncol. 2017;28:1817-1824.</li>
    <li>Nahleh Z, Botrus G, Dwivedi A, et al. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2negative breast cancer A metaanalysis of randomized controlled trials. Mol Clin Oncol. 2019;10:357-365.</li>
    <li>Ribatti D, Tamma R, Annese T. EpithelialMesenchymal transition in cancer A historical overview. Transl Oncol. 2020;13:100773.</li>
    <li>Zhao Q, Li B, Gao Q, et al. Prognostic value of epithelialmesenchymal transition Circulating tumor cells in female breast cancer A metaanalysis. Front Oncol. 2022;12:1024783.</li>
    <li>Sinn BV, Sychra K, Untch M, et al. Ontreatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res. 2024;26:138.</li>
  </ul>

</body>
</html></div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="https://pmc.ncbi.nlm.nih.gov/articles/12337404/" target="_blank">ğŸ‘‰ æŸ¥çœ‹åŸå§‹æ–°è</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>